PPARδ agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-10. Numbers and descriptions here follow the published literature rather than marketing material.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516; GW-1516; endurobol | GW501516 is the research code |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator |
| Molecular formula | C21H18F3NO3S2 | Established chemical formula |
| Molar mass | 453.5 g/mol | Calculated from the formula |
| Regulatory status | Prohibited in sport; not approved as medicine | Status varies by country |
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
== Early life and education == Coon was born in Mount Pleasant, Michigan. He earned his B.Sc. from Central Michigan University in 1998, and received his Ph.D. from the University of Florida in 2002, where he worked with Willard Harrison.
== External links == Clinical trial number NCT06470828 for "A Study of TAK-861 for the Treatment of Narcolepsy Type 1" at ClinicalTrials.gov Clinical trial number NCT06505031 for "A Study of TAK-861 in People With Narcolepsy Type 1" at ClinicalTrials.gov
== Career == Following his Doctoral degree, Greenspan joined Yale University School of Medicine as a Postdoctoral fellow in the Department of Genetics. In 1984, he was appointed as an Associate Research Scientist in the Department of Genetics and was supported by a fellowship from the Arthritis Foundation. His postdoctoral studies at Yale included analysis of RNA splicing and identification of new human HLA genes. He subsequently joined the University of Wisconsin-Madison School of Medicine in 1986 as assistant professor in the Department of Pathology and Laboratory Medicine. Greenspan was promoted to Associate Professor in 1992, and became a Professor in 1997. From 2010 – 2014 Greenspan served as founding/interim chair of the Department of Cell and Regenerative Biology at the University of Wisconsin School of Medicine and Public Health. Prior to that, he was Vice Chair for Research in the Department of Pathology and Laboratory Medicine from 2003 to 2006.
Sources: en.wikipedia.org
Clocks, watches, and instruments dating from the first half of the 20th century, often in military applications, may have been painted with radioactive luminous paint. They are usually no longer luminous; this is not due to radioactive decay of the radium (which has a half-life of 1600 years) but to the fluorescence of the zinc sulfide fluorescent medium being worn out by the radiation from the radium. Originally appearing as white, most radium paint from before the 1960s has tarnished to yellow over time. The radiation dose from an intact device is usually only a hazard when many devices are grouped together or if the device is disassembled or tampered with.
== Function == Arginase catalyzes the hydrolysis of arginine to ornithine and urea. In addition to arginase-1, there also exists a second type arginase-2, which differs in its tissue distribution, subcellular localization, immunologic crossreactivity and physiologic function. The type I isoform encoded by this gene, is a cytosolic enzyme and expressed predominantly in the liver as a component of the urea cycle. Inherited deficiency of this enzyme results in argininemia, an autosomal recessive disorder characterized by hyperammonemia. Two transcript variants encoding different isoforms have been found for this gene.
The death of Yazid in 683 led to a major leadership crisis in the caliphate, and "the power of his house seemed to collapse everywhere", in the words of Orientalist Julius Wellhausen. Ubayd Allah initially neglected to support Yazid's son and designated successor, Mu'awiya II and secured oaths of allegiance to himself from the Basran Arab nobility. In a speech addressed to them, he emphasized his connection to Basra and promised to maintain the wealth of the city's inhabitants. Nonetheless, the Basrans turned against him, forcing him to abandon his palace. He was replaced by Abd Allah ibn al-Harith, a member of the Banu Hashim. Ubayd Allah took refuge with the Azdi chieftain Mas'ud ibn Amr in late 683 or early 684. He plotted to restore his governorship by encouraging Mas'ud to form an alliance of the Yamani and Rabi'a tribes against his opponents from the Banu Tamim and Ibn al-Harith. Mas'ud took to the pulpit of Basra's mosque to stir up the revolt, but Tamimi tribesmen under Ibn al-Harith and their asawira allies under Mah-Afridhun, stormed the building and killed Mas'ud. After Mas'ud's death, Ubayd Allah fled the city practically alone in March 684, taking the Syrian desert route to Hawran or Palmyra. In his rush to escape, he left his wife and family behind. When Ubayd Allah arrived in Syria, he found it in political disarray; Caliph Mu'awiya II had died weeks into his rule and a power vacuum ensued with many Syrian noblemen, particularly from the Qaysi tribes, switching allegiance to the rival, Mecca-based caliphate of Abd Allah ibn al-Zubayr.
Column C is the original assignment by Corey and Pauling. Column K is that of Koltun's patent. Column J is the color scheme used by the molecular visualizer Jmol. Column R is the scheme used by Rasmol; when two colors are shown, the second one is valid for versions 2.7.3 and later. Column P consists of the colors in the PubChem database managed by the United States National Institute of Health. All colors are approximate and may depend on the display hardware and viewing conditions.
Sources: en.wikipedia.org
== Use and effects == According to Albert Hofmann and colleagues, iso-LSD is inactive as a psychedelic in humans at doses of up to 500 μg, which is up to 25 times the minimum given doses of LSD (i.e., 20–50 μg). In other sources, iso-LSD was also stated as being inactive at doses of up to 50 μg/kg (3.5 mg for a 70-kg person), whereas LSD is active at a dose of 1 μg/kg (70 μg for a 70-kg person). Hence, iso-LSD is inactive in humans at doses of up to 50 times those of a common psychedelic dose of LSD and at doses of up to 175 times the minimum dose of LSD. Alexander Shulgin has additionally reported that iso-LSD was inactive at a dose of 4 mg orally. The related drug isoergine is known to be active in terms of psychoactive and hallucinogenic effects at doses of 2 to 5 mg orally.
Use of oxytocin has been found to significantly shorten labor duration. Early oxytocin augmentation has also been found to increase the probability of spontaneous vaginal delivery and reduce the risk of chorioamnionitis or intrauterine infection. Since a landmark investigation was published in JAMA Pediatrics by researchers in 2013, the potential link between oxytocin use during childbirth and increased risks of Autism Spectrum Disorder (ASD) in children's development has been a topic of debate. There is no robust evidence in support of oxytocin causing ASD or other neurodevelopmental disorders. Oxytocin was added to the Institute for Safe Medication Practices's list of High Alert Medications in Acute Care Settings in 2012. The list includes medications that have a high risk for harm if administered incorrectly. During pregnancy, increased uterine motility has led to decreased heart rate, cardiac arrhythmia, seizures, brain damage, and death in the fetus or neonate. Increased uterine motility is a hallmark of both spontaneous labor and induced labor, therefore the risks associated with uterine motility are not specific to this medication. Use is linked to an increased risk of postpartum depression in the mother. Certain learning and memory functions are impaired by centrally administered oxytocin. Also, systemic oxytocin administration can impair memory retrieval in certain aversive memory tasks. However, oxytocin does seem to facilitate learning and memory specifically for social information.
insertion sequence (IS) Also insertion element or simply insert. Any nucleotide sequence that is inserted naturally or artificially into another sequence. The term is used in particular to refer to the part of a transposable element that codes for those proteins directly involved in the transposition process, e.g. the transposase enzyme. The coding region in a transposable insertion sequence is usually flanked by short inverted repeats, and the structure of larger transposable elements may include a pair of flanking insertion sequences which are themselves inverted.
Sources: en.wikipedia.org
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.
No. It has no approved medical indication in any country. Regulatory agencies have not cleared it for treatment or prevention of any condition.
Early clinical work stopped after rodent carcinogenicity findings. Those animal results raised concerns about long-term human risk, although direct human evidence is lacking. The human relevance of the tumors remains an open scientific question.
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.